PMID- 22728209
OWN - NLM
STAT- MEDLINE
DCOM- 20121123
LR  - 20171116
IS  - 1873-2747 (Electronic)
IS  - 0361-9230 (Linking)
VI  - 88
IP  - 6
DP  - 2012 Sep 1
TI  - Centrally administered apelin-13 induces depression-like behavior in mice.
PG  - 574-80
LID - 10.1016/j.brainresbull.2012.06.003 [doi]
AB  - Apelin, a novel bioactive peptide highly concentrated in the brain, is identified 
      as the endogenous ligand for angiotensin-like 1 receptor (APJ). The present study 
      was designed to investigate the effect of apelin-13 on emotion-related behavior 
      using the forced swimming test (FST) and tail suspension test (TST). 
      Intracerebroventricular (i.c.v.) administration of apelin-13 (0.3, 1 and 
      3mug/mouse) dose-dependently increased the immobility time in the FST and TST, 
      compared with control group. However, the APJ receptor antagonist apelin-13(F13A) 
      (0.3-10mug/mouse, i.c.v.) had no influence on immobility time in the FST. The 
      increase of immobility time induced by apelin-13 was significantly blocked by 
      apelin-13(F13A), non-selective opioid receptor antagonist naloxone and kappa-opioid 
      receptor antagonist nor-binaltorphimine dihydrochloride (nor-BNI), respectively, 
      but not the non-selective corticotrophin-releasing factor (CRF) receptor 
      antagonist alpha-helical CRF(9-41) in the FST. In order to eliminate the possibility 
      of a false-positive result in the FST or TST, spontaneous activity and motor 
      function were checked. The results demonstrate that apelin-13 alone or 
      antagonists co-administered with apelin-13 did influence spontaneous activity 
      counts. And apelin-13 had no effect on the motor behavior in the rotarod test and 
      wire hanging test. These results indicate that centrally administered apelin-13 
      elicited depression-like behavior in mice, which was mediated via APJ receptor 
      and kappa-opioid receptor, but not CRF receptor.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Lv, Shuang-Yu
AU  - Lv SY
AD  - Institute of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou 
      University, 222 Tianshui South Road, Lanzhou, Gansu 730000, China. 
      lvshy08@lzu.edu.cn
FAU - Qin, Yao-Jun
AU  - Qin YJ
FAU - Wang, Hai-Ting
AU  - Wang HT
FAU - Xu, Ning
AU  - Xu N
FAU - Yang, Yan-Jie
AU  - Yang YJ
FAU - Chen, Qiang
AU  - Chen Q
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120621
PL  - United States
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
RN  - 0 (Apelin Receptors)
RN  - 0 (Aplnr protein, mouse)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Receptors, Corticotropin-Releasing Hormone)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 0 (apelin-13 peptide)
RN  - 0 (apelin-13, Ala(13)-)
RN  - 36B82AMQ7N (Naloxone)
RN  - 36OOQ86QM1 (norbinaltorphimine)
RN  - 5S6W795CQM (Naltrexone)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
RN  - 96118-75-1 (corticotropin releasing hormone (9-41))
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Apelin Receptors
MH  - Corticotropin-Releasing Hormone/pharmacology
MH  - Depression/*chemically induced
MH  - Injections
MH  - Injections, Intraventricular
MH  - Intercellular Signaling Peptides and Proteins/administration & 
      dosage/chemistry/*pharmacology
MH  - Male
MH  - Mice
MH  - Motor Activity/drug effects
MH  - Naloxone/pharmacology
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Peptide Fragments/pharmacology
MH  - Receptor, Angiotensin, Type 1/*agonists/physiology
MH  - Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors
MH  - Receptors, G-Protein-Coupled/*agonists/physiology
MH  - Receptors, Opioid, kappa/antagonists & inhibitors/*physiology
MH  - Rotarod Performance Test
MH  - Single-Blind Method
EDAT- 2012/06/26 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/26 06:00
PHST- 2012/02/24 00:00 [received]
PHST- 2012/06/07 00:00 [revised]
PHST- 2012/06/13 00:00 [accepted]
PHST- 2012/06/26 06:00 [entrez]
PHST- 2012/06/26 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0361-9230(12)00145-1 [pii]
AID - 10.1016/j.brainresbull.2012.06.003 [doi]
PST - ppublish
SO  - Brain Res Bull. 2012 Sep 1;88(6):574-80. doi: 10.1016/j.brainresbull.2012.06.003. 
      Epub 2012 Jun 21.